ATE232874T1 - Prostaglandin-konjugate zur behandlung von knochenkrankheiten - Google Patents

Prostaglandin-konjugate zur behandlung von knochenkrankheiten

Info

Publication number
ATE232874T1
ATE232874T1 AT99955618T AT99955618T ATE232874T1 AT E232874 T1 ATE232874 T1 AT E232874T1 AT 99955618 T AT99955618 T AT 99955618T AT 99955618 T AT99955618 T AT 99955618T AT E232874 T1 ATE232874 T1 AT E232874T1
Authority
AT
Austria
Prior art keywords
conjugates
treatment
prostaglandin
bone diseases
prostaglandin conjugates
Prior art date
Application number
AT99955618T
Other languages
English (en)
Inventor
Laurent Gil
Yongxin Han
Rejean Ruel
Robert N Young
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Application granted granted Critical
Publication of ATE232874T1 publication Critical patent/ATE232874T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3869—Polyphosphonic acids containing carboxylic acid or carboxylic acid derivative substituents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3865—Polyphosphonic acids containing sulfur substituents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99955618T 1998-11-20 1999-11-18 Prostaglandin-konjugate zur behandlung von knochenkrankheiten ATE232874T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10930798P 1998-11-20 1998-11-20
PCT/CA1999/001111 WO2000031084A1 (en) 1998-11-20 1999-11-18 Prostaglandin conjugates for treating or preventing bone disease

Publications (1)

Publication Number Publication Date
ATE232874T1 true ATE232874T1 (de) 2003-03-15

Family

ID=22326974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99955618T ATE232874T1 (de) 1998-11-20 1999-11-18 Prostaglandin-konjugate zur behandlung von knochenkrankheiten

Country Status (9)

Country Link
US (1) US6121253A (de)
EP (1) EP1131327B1 (de)
JP (1) JP2002530411A (de)
AT (1) ATE232874T1 (de)
AU (1) AU762396B2 (de)
CA (1) CA2351679A1 (de)
DE (1) DE69905488T2 (de)
ES (1) ES2191475T3 (de)
WO (1) WO2000031084A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598246B2 (en) * 1998-04-02 2009-10-06 Mbc Pharma, Inc. Bisphosphonate conjugates and methods of making and using the same
US8586781B2 (en) 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
US6896871B2 (en) 1998-04-02 2005-05-24 Mbc Research, Inc. Biphosphonate conjugates and methods of making and using the same
EP1146050B1 (de) 1999-01-20 2009-12-09 Takara Bio Inc. 4-Substituierte-3,6-Anhydro-Galaktosederivate und ihre pharmazeutische Verwendung
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
DE60003435T2 (de) * 1999-08-04 2004-05-19 The Procter & Gamble Company, Cincinnati Neue 2-decarboxy-2-phosphinico prostaglandin f analoge
WO2001051054A2 (en) * 2000-01-12 2001-07-19 University Of North Carolina - Chapel Hill Use of cyclopentenone derivatives for bone and periodontal regeneration
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
EP1383510B1 (de) * 2001-04-10 2012-10-17 MBC Pharma, Inc. Bisphosphonat-konjugate und verfahren zu ihrer herstellung und verwendung
EP1539185A4 (de) * 2002-05-02 2006-04-05 Osteoscreen Inc Verfahren und zusammensetzungen zur stimulierung des knochenwachstums mit stickoxid freisetzenden bisphosphonat-konjugaten (no-bisphosphonat)
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
CA2618486A1 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
JP2009525976A (ja) * 2006-02-06 2009-07-16 サイプレス バイオサイエンス， インコーポレイテッド ビスホスホネート及び葉酸代謝拮抗剤を含む組成物
US20100099640A1 (en) * 2007-05-04 2010-04-22 Joannes Geuns Tissue degeneration protection
US20090124695A1 (en) 2007-11-14 2009-05-14 Cayman Chemical Company Prostaglandin e1 and e2 analogs for the treatment of various medical conditions
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
CA2738045C (en) * 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
AU2012290089B2 (en) 2011-08-01 2016-09-29 Mbc Pharma, Inc. Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
EP3307747A4 (de) 2015-06-12 2019-02-27 Simon Fraser University Amid-verlinkte ep4-agonist-bisphosphonatverbindungen und verwendungen davon
US11793452B2 (en) 2019-10-03 2023-10-24 Johnson & Johnson Consumer Inc. Method of visualizing and quantifying remineralization

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975404A (en) * 1971-05-04 1976-08-17 The Upjohn Company Bicyclic lactone intermediates
US3927197A (en) * 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
US4018892A (en) * 1975-08-06 1977-04-19 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4097601A (en) * 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4171331A (en) * 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
DE3587956T2 (de) * 1984-04-30 1995-05-24 Procter & Gamble Ausrüstung für die Verwendung bei der Behandlung von Osteoporose.
JPS6191137A (ja) * 1984-10-11 1986-05-09 Kao Corp 外用薬剤組成物
DE3519361A1 (de) * 1985-05-30 1986-12-04 Boehringer Ingelheim International GmbH, 6507 Ingelheim (gamma)-ifn als wirkstoff zur hemmung (verhinderung) von abbauprozessen im knochen
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
US5071840A (en) * 1986-12-19 1991-12-10 Norwich Eaton Pharmaceuticals, Inc. Certain heterocyclic substituted diphosphonate compounds pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism
DK224589A (da) * 1988-05-09 1989-11-10 Merck & Co Inc Polymalonsyreforbindelse og farmaceutisk praeparat indeholdende en saadan forbindelse
JPH0778024B2 (ja) * 1988-10-14 1995-08-23 藤沢薬品工業株式会社 医薬化合物とジホスホン酸誘導体の結合体を含有する医薬用製剤
JPH0759505B2 (ja) * 1988-11-17 1995-06-28 帝人株式会社 シクロペンテノン類を活性成分とする骨形成促進剤
US5071655A (en) * 1990-01-12 1991-12-10 Baylink David J Pharmaceutical combination for treatment of bone-wasting diseases
EP0496520A1 (de) * 1991-01-22 1992-07-29 Merck & Co. Inc. Knochenaktive Verbindungen
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
JPH07507315A (ja) * 1992-05-29 1995-08-10 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド カルシウムおよびホスフェート代謝異常治療用含硫ホスホネート化合物
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis

Also Published As

Publication number Publication date
EP1131327A1 (de) 2001-09-12
DE69905488D1 (de) 2003-03-27
WO2000031084A1 (en) 2000-06-02
JP2002530411A (ja) 2002-09-17
AU762396B2 (en) 2003-06-26
CA2351679A1 (en) 2000-06-02
DE69905488T2 (de) 2003-12-24
AU1255600A (en) 2000-06-13
US6121253A (en) 2000-09-19
EP1131327B1 (de) 2003-02-19
ES2191475T3 (es) 2003-09-01

Similar Documents

Publication Publication Date Title
ATE232874T1 (de) Prostaglandin-konjugate zur behandlung von knochenkrankheiten
SE9901272D0 (sv) New improved formulation
BR0016058A (pt) Compostos de fosfonato
DE69331326D1 (de) Prostaglandin-analoga zur behandlung von osteoporose
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
ATE293450T1 (de) Verwendung von biphosphonsäuren zur behandlung von angiogenese
ATE235244T1 (de) Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
ATE277026T1 (de) Naphthylverbindungen, zusammensetzungen und verfahren
DE60212621D1 (de) Verabreichung von bisphosphonaten durch inhalation zur behandlung von knochenresorption und osteoporosis
DE69922525D1 (de) Pflanzenextrakte zur behandlung einer gesteigerten knochenresorption
ATE291921T1 (de) Verwendung von bisphosphonaten zur behandlung von osteogenese imperfecta
IS4392A (is) Pýridýlbisfosfónöt til notkunar sem efni til lækninga
HUP0202396A2 (hu) Törések kezelésére alkalmas gyógyszerkészítmények
DE69921346D1 (de) Pflanzenextrakte zur behandlung einer gesteigerten knochenresorption
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs
ATE263566T1 (de) Medizinische zusammensetzungen zur behandlung von knochenschäden im multiplen myelom
DE50108711D1 (de) Verwendung von substituierten 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
ATE346036T1 (de) Antiangiogene substanz zur behandlung von krebs, arthritis und netzhauterkrankungen
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE59309063D1 (de) Verwendung von östriol zur herstellung einen transdermalen therapeutischen systeme zur behandlung von klimakterischer osteoporose
ATE224735T1 (de) Mittel zur spezifischen hemmung osteoklastärer knochenresorption
DE69915849D1 (de) Verwendung von gnrh analogen zur behandlung von schizophrenie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties